Taken together, targeting cancer metabolism in NSCLC has become a well-established concept [54], especially in targeting GLUT1, which facilitates glycolysis and promotes NSCLC via integrin β1/Src/FAK signaling [55]. Here, PTK2 is linked to cancer.